❌

Normal view

Artificial intelligence in hepatopathy diagnosis and treatment: Big data analytics, deep learning, and clinical prediction models

World J Gastroenterol. 2025 Dec 14;31(46):111176. doi: 10.3748/wjg.v31.i46.111176.

ABSTRACT

Artificial intelligence (AI) is rapidly transforming the landscape of hepatology by enabling automated data interpretation, early disease detection, and individualized treatment strategies. Chronic liver diseases, including non-alcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma, often progress silently and pose diagnostic challenges due to reliance on invasive biopsies and operator-dependent imaging. This review explores the integration of AI across key domains such as big data analytics, deep learning-based image analysis, histopathological interpretation, biomarker discovery, and clinical prediction modeling. AI algorithms have demonstrated high accuracy in liver fibrosis staging, hepatocellular carcinoma detection, and non-alcoholic fatty liver disease risk stratification, while also enhancing survival prediction and treatment response assessment. For instance, convolutional neural networks trained on portal venous-phase computed tomography have achieved area under the curves up to 0.92 for significant fibrosis (F2-F4) and 0.89 for advanced fibrosis, with magnetic resonance imaging-based models reporting comparable performance. Advanced methodologies such as federated learning preserve patient privacy during cross-center model training, and explainable AI techniques promote transparency and clinician trust. Despite these advancements, clinical adoption remains limited by challenges including data heterogeneity, algorithmic bias, regulatory uncertainty, and lack of real-time integration into electronic health records. Looking forward, the convergence of multi-omics, imaging, and clinical data through interpretable and validated AI frameworks holds great promise for precision liver care. Continued efforts in model standardization, ethical oversight, and clinician-centered deployment will be essential to realize the full potential of AI in hepatopathy diagnosis and treatment.

PMID:41479639 | PMC:PMC12754151 | DOI:10.3748/wjg.v31.i46.111176

A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer

npj Digital Medicine, Published online: 31 December 2025; doi:10.1038/s41746-025-02260-3

A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer
  • ✇STAT
  • Opinion: New medical technology presents hospitals with a prisoner’s dilemma James L. Whiteside and Dmitry Tumin
    In 2026, Medtronic plans to launch a new robot to compete with a legacy market leader. This new robot is reportedly cheaper both in startup and sustained costs. That’s a welcome direction for any new medical technology, but it ignores a problem that hospitals, especially rural ones, face relating to technology and physician training. Sometimes, rational decisions made in isolation lead to irrational outcomes for everyone involved. This is the lesson of the prisoner’s dilemma, a classic game t
     

Opinion: New medical technology presents hospitals with a prisoner’s dilemma

2 January 2026 at 17:30

In 2026, Medtronic plans to launch a new robot to compete with a legacy market leader. This new robot is reportedly cheaper both in startup and sustained costs. That’s a welcome direction for any new medical technology, but it ignores a problem that hospitals, especially rural ones, face relating to technology and physician training.

Sometimes, rational decisions made in isolation lead to irrational outcomes for everyone involved. This is the lesson of the prisoner’s dilemma, a classic game theory puzzle demonstrating how cooperation and self-interest often clash. In the puzzle, two prisoners are each offered a deal: Inform on the other and go free, or stay silent and face a lighter sentence together. Fearing betrayal, both inform and both lose.

Read the rest…

© PASCAL POCHARD-CASABIANCA/AFP via Getty Images

  • ✇STAT
  • STAT+: Who will pay for AI in health care? 3 trends to watch in 2026 Katie Palmer
    The health care industry is gearing up for a battle over whether and how clinical artificial intelligence should get paid for.  As of the end of September, the Food and Drug Administration has authorized 1,357 AI-enabled medical devices. But very few of those tools are actively paid for by insurers.  Some health policy experts and clinicians don’t see that as a problem. Continue to STAT+ to read the full story…
     

STAT+: Who will pay for AI in health care? 3 trends to watch in 2026

2 January 2026 at 17:30

The health care industry is gearing up for a battle over whether and how clinical artificial intelligence should get paid for. 

As of the end of September, the Food and Drug Administration has authorized 1,357 AI-enabled medical devices. But very few of those tools are actively paid for by insurers. 

Some health policy experts and clinicians don’t see that as a problem.

Continue to STAT+ to read the full story…

© Christine Kao/STAT

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial

Nature Medicine, Published online: 02 January 2026; doi:10.1038/s41591-025-04043-5

Results of the phase 1/2 TACTOPS trial show that autologous T cell therapy targeting PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1 in patients with pancreatic ductal adenocarcinoma is feasible and safe, and leads to encouraging clinical responses and evidence of antigen spreading in responders.
❌